Literature DB >> 15750401

Lopinavir/ritonavir maintenance monotherapy after successful viral suppression with standard highly active antiretroviral therapy in HIV-1-infected patients.

Rafael E Campo, Rose Lalanne, Thomas J Tanner, Dushyantha T Jayaweera, Allan E Rodriguez, Lunie Fontaine, Michael A Kolber.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2005        PMID： 15750401     DOI： 10.1097/01.aids.0000161777.38438.ed

Source DB:  PubMed          Journal:  AIDS        ISSN： 0269-9370            Impact factor:   4.177


× No keyword cloud information.
  2 in total

1.  Protease inhibitor resistance analysis in the MONARK trial comparing first-line lopinavir-ritonavir monotherapy to lopinavir-ritonavir plus zidovudine and lamivudine triple therapy.

Authors:  Constance Delaugerre; Philippe Flandre; Marie Laure Chaix; Jade Ghosn; François Raffi; Pierre Dellamonica; H Jaeger; D Shürmann; Isabelle Cohen-Codar; Philippe Ngo Van; Michael Norton; Anne-Marie Taburet; Jean-François Delfraissy; Christine Rouzioux
Journal:  Antimicrob Agents Chemother       Date:  2009-05-18       Impact factor: 5.191

2.  Week 120 efficacy of tenofovir, lamivudine and lopinavir/r-based second-line antiretroviral therapy in treatment-experienced HIV patients.

Authors:  Yang Han; Yijia Li; Jing Xie; Zhifeng Qiu; Yanling Li; Xiaojing Song; Ting Zhu; Taisheng Li
Journal:  PLoS One       Date:  2015-03-30       Impact factor: 3.240
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.